Epix Considers Selling Vasovist If Imaging Agent Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA agrees to accept a “blinded re-read” of data on the vascular imaging agent as an NDA amendment after Epix appealed “approvable” requests for more studies.
You may also be interested in...
Epix Looks To Partner With Path Now Clear For Vasovist Approval
Epix will file an NDA in mid-2008 following positive results from reevaluation of the vascular imaging agent.
Epix Looks To Partner With Path Now Clear For Vasovist Approval
Epix will file an NDA in mid-2008 following positive results from reevaluation of the vascular imaging agent.
Epix Will Resubmit Vasovist NDA By Mid-Year
End appears near in long road to approval for vascular imaging agent after FDA and Epix agree on plan for Phase III study image re-reads.